BACK
Gwendolyn Melnyk
Vice President
New York Office | gwen.melnyk@torreya.com | 212.257.6039
Gwendolyn Melnyk, a Vice President at Torreya, specializes in North American strategic transactions.
Before joining Torreya in 2017, Gwen was an Associate in healthcare investment banking for Jefferies LLC working on sell- and buy-side M&A deals and debt and equity financings. Prior to Jefferies, she worked as a Research Associate for Regeneron Pharmaceuticals, Inc. and earlier as a Research and Development Associate for Cytimmune Sciences, Inc.
Gwen earned a B.A. in chemical and biomolecular engineering and an M.A. in biotechnology from John Hopkins University. She also earned an M.B.A. in finance and management from New York University.
Selected Transactions
|
| Sale to |
|
|
$73 million
May 2022
|
|
| Licensing of LM-302 to |
|
|
Up to $1.2 billion in milestones + royalties ($25 million upfront)
May 2022
|
|
| Acquisition of Serenity LLC and global rights to Noctiva™ |
|
|
$41 million + milestones and royalties
March 2022
|
|
| Sale of E7777 to |
|
|
$40 million upfront + $76mm milestones
September 2021
|
|
| Sale to |
|
|
June 2021
|
|
| Exclusive license agreement to commercialize Triferic® in South Korea with |
|
|
September 2020
|
|
| Sale of Noden to |
|
|
Up to $52.83 Million
September 2020
|
|
| License of NOV03 in North America to |
|
|
December 2019
|
|
| Research collaboration and license agreement for RIG-I pathway with |
|
|
Up to $505 million
December 2018
|